Skip to content

ImmunoVec

6 viewers · 30d

Total raised

$12.7M

+$12.7M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $12.7M
ROUNDS
1
INVESTORS
10
FOUNDED
N/A
HQ
Los Angeles, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
6

AI overview

Updated

ImmunoVec is a Los Angeles biotechnology company developing in vivo cell therapies that use programmable DNA medicines to engineer specific cell types directly inside the patient's body. Its platform combines cell type-specific synthetic promoters with multiple delivery vehicles, including viral vectors and non-viral systems such as DNA-loaded polymeric nanoparticles. The company launched from stealth with an up-to-$40.7 million ARPA-H EMBODY award to advance a first-in-class in vivo cell therapy for autoimmune diseases from pre-clinical studies through a first-in-human trial, and also targets solid tumors and genetic disorders.

What sets it apart

Delivery-agnostic precision: proprietary cell type-specific expression cassettes ensure a therapy is expressed only in the intended cells regardless of the delivery vehicle, mitigating off-target risk, and the same cassettes work across viral vectors, lipid nanoparticles, polymeric nanoparticles, and exosomes.

Funding history

1 round
Equity+2Jun 29, 2026
Form D
+$12.7M$12.7M total

Latest SEC filings

via EDGAR · CIK 0001914272
Form D · Jun 29, 2026NewView on EDGAR

Products

1 tracked

In vivo cell engineering platform

Cell and gene therapy platform

A platform of programmable DNA medicines that reprogram immune and other cell types directly within the body, led by a pre-clinical in vivo cell therapy program for autoimmune diseases funded by the ARPA-H EMBODY program.

  • Cell type-specific synthetic promoters for precise expression
  • Delivery-agnostic expression cassettes usable across viral and non-viral vehicles
  • DNA-loaded polymeric nanoparticle delivery
  • Lead autoimmune-disease program funded through first-in-human trial by ARPA-H

Links

WebsiteLinkedInSEC EDGAR filings